Areas of Interest

Areas of Interest

Innovation through external collaboration

We are interested in innovative projects and can support these from funding through first studies in man and beyond. We have capabilities in both small molecules and biologics.

We focus on the therapeutic areas listed below:

  • Oncology
  • Diabetes & Metabolic disorders
  • CNS
  • Orphan diseases
  • Others: Eye disorders, Other disease areas

Small molecule partnerships

Our New Drug & Bio Research Department is focusing on the discovery and development of drug candidates in a variety of therapeutic areas to fulfill unmet medical needs. We are building and improving our project portfolio through internal research as well as external collaborations with leading academic laboratories and biotech companies.

For diabetes & metabolic disorders, we are engaged in specific projects in Type II diabetes, hyperlipidemia, and obesity. We have several Fixed-Dose Combination programs and are also active in the fields of digestive disorders, pain relief and CNS by developing various dosage forms (tablet, patch, plaster etc.) in the Pharmaceutical Research Department.

Biologics partnerships

Handok is sharing proprietary technology named “hybrid-Fc” with Genexine. Hybrid-Fc is a platform technology to construct a long-acting Fc fusion protein hybridized with IgD and IgG4. Handok is building biologic pipelines on our own or by partnering with other companies. One of the biologic products, GX-H9, has advanced to Phase 2 stage of clinical development. GX-H9 (hGH-hyFc) is a novel, long-acting hybrid Fc-fused human growth hormone showing potential for both weekly and every-other-week administration, targeting both adult and pediatric patients with growth hormone deficiency. Handok is interested in seeking opportunities for co-development and licensing-out of our products. Handok focuses on high-priority therapeutic areas, with special interest in immunology, oncology and orphan diseases.

Medical device (DENEX)

The DENEX System is composed of an ablation catheter and an RF generator. The system targets to treat resistant hypertension by ablating sympathetic nerves located along renal arteries.

DENEX System Key features

  • Multi-electrode catheter efficiently designed for renal denervation (4 patents for design and manufacturing)
  • Delivered with a 0.014″ guide wire
  • Minimized for both femoral and radial access
  • MEMS-based contact sensors implemented on all the electrodes (DENEX 2.0)
  • Dedicated and intuitively-operative RF generator

DRM technology (Dual Release Micro-coating technology)

DRM technology in one of unique patent technology for fixed-dose combination by introducing intermediate coating layer for inducing independent release and minimize chemical drug-drug interaction of two APIs to secure product quality

Marketed Products

  • Amaryl M SR®
    FDC of Metformin + Glimepiride IR
  • Tenelia M®
    FDC of Metformin + Teneligliptin IR

API-1 sustained-matrix core

  • Sustained release
  • Gastro-retentive

Intermediated coating layer

  • Independent release of API-1 & API-2
  • Minimize chemical drug-drug interaction

API-2 micro-coating layer

  • Immediate release
  • Maintain homogeneity through
    micro-coating technology
  • Glimepiride dissolve first

    Immediate release of glimepiride coated on the outer layer

  • Metformin Core swelling and release

    Sustained release of metformin Through the polymer network

Long acting protein therapeutics (Collaboration with Genexine)

More flexible Hinge Less ADCC activity

lgD lgG4
  • More desirable to bind
    by flexible hinge

  • Less toxicty

  • Long half-life
    up to 2~4 weeks

hyFc fusion Technology (Genexine’s Proprietary Technology)

Overcome steric hindrance and Fc related toxicity by combining flexible IgD hinge and less toxic lgG4 Fc